ArticleJGH open : an open access journal of gastroenterology and hepatology2024
Clinical utility of C-reactive protein-to-albumin ratio in the management of patients with inflammatory bowel disease.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06750315 (CRP/ Albumin Ratio and Neutrophil Lymphocyte Ratio in Predicting Activity in IBD Patients), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CRP/ Albumin Ratio and Neutrophil Lymphocyte Ratio in Predicting Activity in IBD Patients
Who cites it
8 citing papers in PubMed, 5 citations in OpenAlex.
- C-Reactive Protein-to-Albumin Ratio in Pediatric Inflammatory Bowel Disease: Associations with Disease Activity and Comparison with C-Reactive Protein Alone.Diagnostics (Basel, Switzerland) · 2026Article
- Advancing Predictive Modeling of Inflammatory Bowel Disease (IBD) Flares: A Data-Driven Approach Using Lifestyle and Psychosocial Factors from a Remote Monitoring Platform.Digestive diseases and sciences · 2026Observational
- Albumin-Based Indices and Hematologic Ratios as Predictors of Short-Term Response to Anti-TNF Therapy in Crohn's Disease: A Single-Center Retrospective Study.Life (Basel, Switzerland) · 2026Article
- Modified Glasgow Prognostic Score as a dual biomarker for disease activity and malnutrition in inflammatory bowel disease.Scientific reports · 2026Article
- Review
- The clinical utility of combining D-dimer with the C-reactive protein/albumin ratio for assessing treatment response in pediatric infectious mononucleosis.Frontiers in medicine · 2026Article
- Review Article: Albumin and Its Role in Inflammatory Bowel Disease: The Old, the New, and the Future.Journal of gastroenterology and hepatology · 2025Review
- The ability of C-reactive protein-albumin ratio to predict disease activity in ulcerative colitis.Biomarkers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: C-reactive protein (CRP)-to-albumin ratio (CAR) is a novel score with prognostic value in inflammatory conditions. This study assessed the performance of CAR as an objective marker of disease activity and prediction of subtherapeutic infliximab trough levels in patients with inflammatory bowel disease (IBD). Methods: A retrospective study was conducted on three different patient cohorts with IBD: patients who had (i) fecal calprotectin (FC) measurements; (ii) Mayo Endoscopic Scores; and (iii) infliximab trough levels available. The relative performances of CAR, albumin, and CRP were compared in predicting disease activity (based on FC or Mayo Endoscopic Score) and infliximab trough levels. Results: In both the FC ( Conclusion: CAR was only a modest discriminator of subtherapeutic infliximab levels and offers little more than CRP in detecting active disease. CAR has potential to detect severe Mayo 3 disease and could be calculated in patients admitted with suspected acute severe ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.